{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:51:42Z","timestamp":1785523902496,"version":"3.56.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National University Ireland, Galway"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Cancer and its treatments often lead to inflammation, muscle problems, and ongoing loss of physical function, as reflected by alterations in circulating microRNAs (miRNAs). In this study, we measured levels of selected muscle- (miR-1, miR-133, miR-208, miR-486, and miR-499) and inflammation-related (miR-21, miR-126, miR-146, and miR-155) miRNAs in breast cancer patients and aimed to explore, using stratified analyses, how their levels relate to cancer subtype, treatment modality, treatment timing, and age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We collected 77 plasma samples from pretreatment and post-treatment breast cancer patients and healthy controls. Circulating miRNA levels were measured using quantitative reverse transcription polymerase chain reaction. We compared miRNA levels across different breast cancer subtypes, treatment modalities, treatment timing, and age groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Pretreatment patients with breast cancer did not show significant changes in the selected miRNAs compared with healthy controls. However, different breast cancer subtypes showed distinct patterns: Luminal A predominantly affected muscle-related miRNAs, and Luminal B affected inflammation-related miRNAs. Cancer treatment, especially surgery and chemotherapy, led to significant changes in miR-21 and miR-486, primarily within the first 91\u00a0days after cancer diagnosis. Increases in miR-133 and miR-486 after treatment were mostly seen in patients over 50\u00a0years old.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Circulating muscle- and inflammation-related miRNAs display distinct expression patterns associated with breast cancer subtype and treatment. Specifically, miR-21, miR-133, and miR-486 demonstrate sensitivity to cancer treatment exposure, timing, and patient age.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11033-026-12472-9","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T10:51:58Z","timestamp":1785235918000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Circulating muscle- and inflammation-related microRNAs in breast cancer survivorship: associations with subtype, treatment, timing, and age"],"prefix":"10.1007","volume":"53","author":[{"given":"Yanping","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Annuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerin","family":"Michael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8920-0815","authenticated-orcid":false,"given":"Ananya","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"issue":"1","key":"12472_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck N et al (2019) Breast cancer. Nat Rev Dis Prim 5(1):1\u201331. https:\/\/doi.org\/10.1038\/s41572-019-0111-2","journal-title":"Nat Rev Dis Prim"},{"issue":"3","key":"12472_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/CAAC.21834","volume":"74","author":"BF Bray","year":"2022","unstructured":"Bray BF et al (2022) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263. https:\/\/doi.org\/10.3322\/CAAC.21834","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"12472_CR3","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/S00520-024-08532-0","volume":"32","author":"MK Jang","year":"2024","unstructured":"Jang MK, Park S, Raszewski R, Park CG, Doorenbos AZ, Kim S (2024) \u201cPrevalence and clinical implications of sarcopenia in breast cancer: a systematic review and meta-analysis.\u201d Supportive Care Cancer 32(5):328. https:\/\/doi.org\/10.1007\/S00520-024-08532-0","journal-title":"Supportive Care Cancer"},{"issue":"4","key":"12472_CR4","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/S11764-012-0234-X","volume":"6","author":"A Villase\u00f1or","year":"2012","unstructured":"Villase\u00f1or A et al (2012) Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL study. J Cancer Surviv 6(4):398\u2013406. https:\/\/doi.org\/10.1007\/S11764-012-0234-X","journal-title":"J Cancer Surviv"},{"key":"12472_CR5","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/168407","author":"JK Onesti","year":"2014","unstructured":"Onesti JK, Guttridge DC (2014) Inflammation based regulation of cancer cachexia. BioMed Res Int. https:\/\/doi.org\/10.1155\/2014\/168407","journal-title":"BioMed Res Int"},{"issue":"11","key":"12472_CR6","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.1016\/S1470-2045(14)70263-3","volume":"15","author":"CI Diakos","year":"2014","unstructured":"Diakos CI, Charles KA, McMillan DC, Clarke SJ (2014) Cancer-related inflammation and treatment effectiveness. Lancet Oncol 15(11):e493\u2013e503. https:\/\/doi.org\/10.1016\/S1470-2045(14)70263-3","journal-title":"Lancet Oncol"},{"key":"12472_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/FPHYS.2018.00409\/BIBTEX","author":"S P\u00e9rez-Baos","year":"2018","unstructured":"P\u00e9rez-Baos S, Prieto-Potin I, Rom\u00e1n-Blas JA, S\u00e1nchez-Pernaute O, Largo R, Herrero-Beaumont G (2018) Mediators and patterns of muscle loss in chronic systemic inflammation. Front Physiol. https:\/\/doi.org\/10.3389\/FPHYS.2018.00409\/BIBTEX","journal-title":"Front Physiol"},{"issue":"4","key":"12472_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12041004","volume":"12","author":"JMO Santos","year":"2020","unstructured":"Santos JMO, Da Silva SP, Gil Da Costa RM, Medeiros R (2020) The emerging role of micrornas and other non-coding rnas in cancer cachexia. Cancers (Basel) 12(4):1\u201314. https:\/\/doi.org\/10.3390\/cancers12041004","journal-title":"Cancers (Basel)"},{"key":"12472_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS20081962","author":"PP Freire","year":"2019","unstructured":"Freire PP et al (2019) The pathway to cancer cachexia: MicroRNA-regulated networks in muscle wasting based on integrative meta-analysis. Int J Mol Sci. https:\/\/doi.org\/10.3390\/IJMS20081962","journal-title":"Int J Mol Sci"},{"issue":"3","key":"12472_CR10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/jcsm.12168","volume":"8","author":"A Narasimhan","year":"2017","unstructured":"Narasimhan A et al (2017) Small RNAome profiling from human skeletal muscle: novel miRNAs and their targets associated with cancer cachexia. J Cachexia Sarcopenia Muscle 8(3):405\u2013416. https:\/\/doi.org\/10.1002\/jcsm.12168","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"12472_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/LIFE11121439","author":"Y Jiang","year":"2021","unstructured":"Jiang Y, Ghias K, Gupta S, Gupta A (2021) MicroRNAs as potential biomarkers for exercise-based cancer rehabilitation in cancer survivors. Life. https:\/\/doi.org\/10.3390\/LIFE11121439","journal-title":"Life"},{"issue":"9","key":"12472_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0024145","volume":"6","author":"MB Kirschner","year":"2011","unstructured":"Kirschner MB et al (2011) Haemolysis during sample preparation alters microRNA content of plasma. PLoS ONE 6(9):e24145. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0024145","journal-title":"PLoS ONE"},{"issue":"7","key":"12472_CR13","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1158\/1535-7163.MCT-12-0802\/93940\/P\/THE-POTENTIAL-ROLE-OF-MIR-451-IN-CANCER-DIAGNOSIS","volume":"12","author":"X Pan","year":"2013","unstructured":"Pan X, Wang R, Wang ZX (2013) The potential role of miR-451 in cancer diagnosis, prognosis, and therapy. Mol Cancer Ther 12(7):1153\u20131162. https:\/\/doi.org\/10.1158\/1535-7163.MCT-12-0802\/93940\/P\/THE-POTENTIAL-ROLE-OF-MIR-451-IN-CANCER-DIAGNOSIS","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"12472_CR14","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1007\/S12282-022-01359-9\/FIGURES\/4","volume":"29","author":"JW Woo","year":"2022","unstructured":"Woo JW, Choi HY, Kim M, Chung YR, Park SY (2022) miR-145, miR-205 and miR-451: potential tumor suppressors involved in the progression of in situ to invasive carcinoma of the breast. Breast Cancer 29(5):814\u2013824. https:\/\/doi.org\/10.1007\/S12282-022-01359-9\/FIGURES\/4","journal-title":"Breast Cancer"},{"key":"12472_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/FGENE.2014.00149\/ABSTRACT","author":"J Zhu","year":"2014","unstructured":"Zhu J et al (2014) Different miRNA expression profiles between human breast cancer tumors and serum. Front Genet. https:\/\/doi.org\/10.3389\/FGENE.2014.00149\/ABSTRACT","journal-title":"Front Genet"},{"issue":"16","key":"12472_CR16","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.1158\/1078-0432.CCR-12-3401\/85841\/AM\/IDENTIFICATION-OF-CIRCULATING-MICRORNA-SIGNATURES","volume":"19","author":"M Chan","year":"2013","unstructured":"Chan M et al (2013) Identification of circulating microRNA signatures for breast cancer detection. Clin Cancer Res 19(16):4477\u20134487. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3401\/85841\/AM\/IDENTIFICATION-OF-CIRCULATING-MICRORNA-SIGNATURES","journal-title":"Clin Cancer Res"},{"issue":"10","key":"12472_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/GB-2007-8-10-R214\/FIGURES\/6","volume":"8","author":"C Blenkiron","year":"2007","unstructured":"Blenkiron C et al (2007) MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 8(10):1\u201316. https:\/\/doi.org\/10.1186\/GB-2007-8-10-R214\/FIGURES\/6","journal-title":"Genome Biol"},{"issue":"6","key":"12472_CR18","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/J.MOLMED.2011.01.006","volume":"17","author":"CA Andorfer","year":"2011","unstructured":"Andorfer CA, Necela BM, Thompson EA, Perez EA (2011) MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer. Trends Mol Med 17(6):313\u2013319. https:\/\/doi.org\/10.1016\/J.MOLMED.2011.01.006","journal-title":"Trends Mol Med"},{"key":"12472_CR19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/J.OMTN.2022.03.009","volume":"28","author":"R Wang","year":"2022","unstructured":"Wang R et al (2022) Skeletal muscle-specific overexpression of miR-486 limits mammary tumor-induced skeletal muscle functional limitations. Mol Ther Nucleic Acids 28:231\u2013248. https:\/\/doi.org\/10.1016\/J.OMTN.2022.03.009","journal-title":"Mol Ther Nucleic Acids"},{"issue":"3","key":"12472_CR20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/S13402-014-0176-6\/FIGURES\/5","volume":"37","author":"L Rask","year":"2014","unstructured":"Rask L et al (2014) Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status. Cell Oncol 37(3):215\u2013227. https:\/\/doi.org\/10.1007\/S13402-014-0176-6\/FIGURES\/5","journal-title":"Cell Oncol"},{"issue":"5","key":"12472_CR21","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/S13402-017-0334-8\/FIGURES\/4","volume":"40","author":"M Sromek","year":"2017","unstructured":"Sromek M et al (2017) Changes in plasma miR-9, miR-16, miR-205 and miR-486 levels after non-small cell lung cancer resection. Cell Oncol 40(5):529\u2013536. https:\/\/doi.org\/10.1007\/S13402-017-0334-8\/FIGURES\/4","journal-title":"Cell Oncol"},{"issue":"1","key":"12472_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12885-017-3753-Z\/FIGURES\/7","volume":"18","author":"C Li","year":"2018","unstructured":"Li C, Zheng X, Li W, Bai F, Lyu J, Meng QH (2018) Serum miR-486-5p as a diagnostic marker in cervical cancer: With investigation of potential mechanisms. BMC Cancer 18(1):1\u201310. https:\/\/doi.org\/10.1186\/S12885-017-3753-Z\/FIGURES\/7","journal-title":"BMC Cancer"},{"issue":"2","key":"12472_CR23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.4103\/GMIT.GMIT_79_20","volume":"11","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Cheng Z (2022) The roles of microRNA-133 in gynecological tumors. Gynecol Minim Invasive Ther 11(2):83. https:\/\/doi.org\/10.4103\/GMIT.GMIT_79_20","journal-title":"Gynecol Minim Invasive Ther"},{"issue":"5","key":"12472_CR24","doi-asserted-by":"publisher","first-page":"7109","DOI":"10.1002\/JCB.27984","volume":"120","author":"AR Hesari","year":"2019","unstructured":"Hesari AR et al (2019) Expression of circulating miR-17, miR-25, and miR-133 in breast cancer patients. J Cell Biochem 120(5):7109\u20137114. https:\/\/doi.org\/10.1002\/JCB.27984","journal-title":"J Cell Biochem"},{"issue":"2","key":"12472_CR25","doi-asserted-by":"publisher","first-page":"777","DOI":"10.26355\/EURREV_202001_20060","volume":"24","author":"ZZ Zheng","year":"2020","unstructured":"Zheng ZZ et al (2020) Serum miR-133 as a novel biomarker for predicting treatment response and survival in acute myeloid leukemia. Eur Rev Med Pharmacol Sci 24(2):777\u2013782. https:\/\/doi.org\/10.26355\/EURREV_202001_20060","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"12472_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/S10549-014-3079-3\/FIGURES\/3","volume":"147","author":"V M\u00fcller","year":"2014","unstructured":"M\u00fcller V et al (2014) Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: A translational research project within the Geparquinto trial. Breast Cancer Res Treat 147(1):61\u201368. https:\/\/doi.org\/10.1007\/S10549-014-3079-3\/FIGURES\/3","journal-title":"Breast Cancer Res Treat"},{"key":"12472_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-36321-3","author":"S Khalighfard","year":"2018","unstructured":"Khalighfard S, Alizadeh AM, Irani S, Omranipour R (2018) Plasma miR-21, miR-155, miR-10b, and Let-7a as the potential biomarkers for the monitoring of breast cancer patients. Scientific Rep. https:\/\/doi.org\/10.1038\/s41598-018-36321-3","journal-title":"Scientific Rep"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12472-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12472-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12472-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:29:56Z","timestamp":1785518996000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12472-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12472"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12472-9","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval for the current study was obtained from the Clinical Research Ethics Committee of University Hospital Galway\n                      \n                      (Ref: C.A. 2828 \u2013 Identification and characterization of biomarkers that determine the quality of life of cancer survivors). The Clinical Research Ethics Committee operates in accordance with the World Medical Association Declaration of Helsinki, which provides the core ethical principles for medical research involving human subjects. The committee reviews applications to ensure they meet the Declaration of Helsinki, EU Directives, and national legislation regarding ethical research conduct. All experiments were conducted in line with the approved ethical protocols and were carried out in accordance with Clinical Research Ethics Committee guidelines. All experimental protocols were approved by the Clinical Research Ethics Committee prior to the start of the study. A written informed consent was obtained from all participants ensuring participants voluntarily agree, were fully informed, and could withdraw at any time. All data were collected, stored, and managed in accordance with the General Data Protection Regulation 2016 and Data Protection Act 2018.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1287"}}